Huayuan Biological: Shareholders plan to reduce their stake by no more than 1% of the company's shares.

Genor Biopharma announced that shareholder Huaruishengyin and its concerted parties plan to reduce their holdings by no more than 6.49 million shares, accounting for 1% of the company's total share capital. The reduction period is from May 30, 2025 to August 29, 2025, and the reduction methods are through centralized bidding and block trading.